Nurix Therapeutics, Inc.

Report azionario NasdaqGM:NRIX

Capitalizzazione di mercato: US$1.7b

Nurix Therapeutics Dividendi e riacquisti

Criteri Dividendo verificati 0/6

Nurix Therapeutics non ha registrato alcun pagamento di dividendi.

Informazioni chiave

n/a

Rendimento del dividendo

-15.1%

Rendimento del riacquisto

Rendimento totale per gli azionisti-15.1%
Rendimento futuro dei dividendi0%
Crescita dei dividendin/a
Prossima data di pagamento dei dividendin/a
Data di stacco del dividendon/a
Dividendo per azionen/a
Rapporto di remunerazionen/a

Aggiornamenti recenti su dividendi e riacquisti

Nessun aggiornamento

Recent updates

Seeking Alpha • Apr 09

Nurix: 'Strong Buy' Bexobruditeg Development And Dual Degrader Zelebrudomide

Summary Nurix Therapeutics, Inc. maintains a Strong Buy rating, driven by the advancement of bexobrutideg for relapsed/refractory CLL in pivotal phase 2 trials. Company is set to initiate a global phase 3 confirmatory trial for bexobrutideg in mid-2026, targeting patients post-BTK therapy and benchmarking against pirtobrutinib. Expansion efforts include higher-dose bexobrutideg for earlier CLL lines, an oral formulation for immunology, and the dual BTK/IKZF degrader zelebrudomide for B-cell malignancies. While cash reserves stand at $540.7M, NRIX faces a 12-month runway and will require additional funding to sustain its R&D-intensive pipeline. Read the full article on Seeking Alpha
Articolo di analisi • Nov 16

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stock Rockets 30% As Investors Are Less Pessimistic Than Expected

Nurix Therapeutics, Inc. ( NASDAQ:NRIX ) shareholders have had their patience rewarded with a 30% share price jump in...
Articolo di analisi • Oct 12

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year

Nurix Therapeutics, Inc. ( NASDAQ:NRIX ) missed earnings with its latest quarterly results, disappointing...
Articolo di analisi • Sep 30

Subdued Growth No Barrier To Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) Price

With a median price-to-sales (or "P/S") ratio of close to 10x in the Biotechs industry in the United States, you could...
Articolo di analisi • Aug 18

Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

NasdaqGM:NRIX 1 Year Share Price vs Fair Value Explore Nurix Therapeutics's Fair Values from the Community and select...
Articolo di analisi • Jul 14

Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher

Nurix Therapeutics, Inc. ( NASDAQ:NRIX ) shareholders will have a reason to smile today, with the analysts making...
Articolo di analisi • May 12

Shareholders Will Probably Hold Off On Increasing Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) CEO Compensation For The Time Being

Key Insights Nurix Therapeutics' Annual General Meeting to take place on 19th of May CEO Arthur Sands' total...
Seeking Alpha • Apr 17

Nurix Therapeutics: IRAK4 GS-6971 Isn't Only Protein Degrader With Big Potential

Summary FDA IND clearance given for BTK degrader GS-6791, targeting inflammatory disorders, allowing Nurix Therapeutics, Inc. to receive a $5 million milestone payment from Gilead Sciences. Nurix has earned $135 million from its Gilead collaboration and could earn up to a total of $420 million in milestone payments for developing up to five protein degraders. Nurix's wholly owned BTK degrader Bexobrutideg is in phase 1b trials for relapsed/refractory B-cell malignancies, with plans to target inflammatory and autoimmune disorders as well. Besides the partnership with Gilead Sciences, the company is advancing its STAT6 protein degrader with Sanofi and antibody drug conjugate degraders as a new class of drugs to target disorders with Pfizer. Read the full article on Seeking Alpha
Articolo di analisi • Apr 17

Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher

Nurix Therapeutics, Inc. ( NASDAQ:NRIX ) shareholders will have a reason to smile today, with the analysts making...
Articolo di analisi • Mar 22

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares May Have Slumped 25% But Getting In Cheap Is Still Unlikely

Unfortunately for some shareholders, the Nurix Therapeutics, Inc. ( NASDAQ:NRIX ) share price has dived 25% in the last...
Seeking Alpha • Feb 18

Nurix Therapeutics: A Story To Monitor

Summary Nurix Therapeutics, Inc.'s shares have dropped some 40% due to limited 2025 data catalysts, despite promising Phase 1 results for NX-5948 in CLL, targeting pivotal trials in 2025. Nurix's DELigase platform leverages E3 ligases for protein modulation, aiming to degrade or elevate proteins, offering advantages over CRISPR and RNA interference methods. NX-5948 shows strong efficacy in heavily pre-treated CLL patients, with Fast Track and PRIME designations, but faces competition from BeiGene's similar BTK degrader. An initial analysis around NRIX stock follows in the paragraphs below. Read the full article on Seeking Alpha
Articolo di analisi • Jan 30

Companies Like Nurix Therapeutics (NASDAQ:NRIX) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. By way of example, Nurix Therapeutics...
Seeking Alpha • Jan 05

Nurix Therapeutics: Still A Cool Story, But This Price Point Remains Too Hot For Me

Summary Nurix Therapeutics (NRIX) focuses on protein degradation in cancer treatment, with a current valuation of $1.4 billion and promising early-stage clinical data. NX-5948, a BTK degrader, shows high response rates in B-cell malignancies, with manageable safety profiles and FDA Fast Track designations. Financially, NRIX holds $99 million in cash and $349 million in marketable securities, but faces risks of future dilution and high execution expectations. Despite compelling early data, NRIX's high valuation and market hype suggest waiting for better entry points, making it a "Hold" for now, in my opinion. Read the full article on Seeking Alpha
Articolo di analisi • Nov 07

Subdued Growth No Barrier To Nurix Therapeutics, Inc. (NASDAQ:NRIX) With Shares Advancing 25%

Despite an already strong run, Nurix Therapeutics, Inc. ( NASDAQ:NRIX ) shares have been powering on, with a gain of...
Articolo di analisi • Oct 31

Companies Like Nurix Therapeutics (NASDAQ:NRIX) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. By way of example, Nurix...
Seeking Alpha • Oct 08

Nurix: An Attractive Early-Stage Biotech Play

Summary Nurix Therapeutics, specializing in targeted protein degradation, shows promise with its clinical-stage candidates NX-1607, NX-5948, and NX-2127 for cancer and autoimmune diseases. Strong partnerships with Sanofi, Gilead, and Pfizer bolster Nurix's funding and technological capabilities, enhancing its potential for successful drug development and commercialization. Despite operating at a loss, Nurix's solid cash position and positive clinical trial results make it a compelling buy opportunity, though risks remain. Nurix's innovative approach and potential regulatory approvals make it a strong investment candidate for those seeking high-risk, high-reward opportunities. Read the full article on Seeking Alpha
Articolo di analisi • Sep 07

Unpleasant Surprises Could Be In Store For Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) Shares

Nurix Therapeutics, Inc.'s ( NASDAQ:NRIX ) price-to-sales (or "P/S") ratio of 24.1x might make it look like a strong...
Seeking Alpha • Sep 04

Nurix Therapeutics: Promising Science, Major Collaborations, Undifferentiated Data

Summary Nurix Therapeutics leverages the ubiquitin-proteasome system for targeted protein degradation (TPD) and elevation (TPE) in cancer and autoimmune diseases, with promising early-stage clinical data. Key programs include BTK, IKZF, and CBL-B targets, with notable molecules NX-5948, NX-2127, and NX-1607 showing potential in heavily pretreated B-cell malignancies. Strategic partnerships with Gilead, Sanofi, and Pfizer provide substantial financial backing, with up to $8.1 billion in potential milestone payments. Despite high valuation and limited near-term data catalysts, Nurix's innovative approach and big pharma interest warrant continued observation for future investment opportunities. Read the full article on Seeking Alpha
Articolo di analisi • Jul 15

Nurix Therapeutics (NASDAQ:NRIX) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, Nurix Therapeutics...
Seeking Alpha • Jun 19

Nurix Therapeutics: Protein Deg Specialist's Latest Data Establishes Bull Case

Summary Nurix Therapeutics raised $209m in its IPO in July 2020, focusing on protein degradation in drug development, primarily in the blood cancer space. Protein degradation involves marking proteins for destruction by the proteasome using bifunctional small molecules. Nurix's lead proprietary candidate NX-5948 showed promising results in a Phase 1a clinical study for CLL patients in data released this week, triggering a surge in the company's share price. Management hopes to guide its lead candidate into a pivotal study next year, opening up a potentially compelling market opportunity. More data - in NHL and immuno-oncology - will arrive this year, and Nurix continues to collaborate with three major Pharma companies - Gilead, Sanofi, and Pfizer. The bull run can therefore be sustained. Read the full article on Seeking Alpha
Articolo di analisi • May 29

What Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 26% Share Price Gain Is Not Telling You

The Nurix Therapeutics, Inc. ( NASDAQ:NRIX ) share price has done very well over the last month, posting an excellent...
Seeking Alpha • Apr 15

Nurix Therapeutics Advances Promising Protein Degraders For B-Cell Malignancies

Summary Nurix Therapeutics raises $175 million in an upsized offering after a 168% stock return in the past six months. The biotech company is developing protein degraders, with NX-2127 and NX-5948, targeting B-cell malignancies. Nurix's protein degraders are focused on BTK, a target also addressed by Johnson & Johnson's popular drug Imbruvica. Hold rating advised: High-risk, high-reward due to innovative approach and competitive market; efficacy and safety data needed. Read the full article on Seeking Alpha
Articolo di analisi • Apr 14

Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 28% Price Boost Is Out Of Tune With Revenues

Nurix Therapeutics, Inc. ( NASDAQ:NRIX ) shares have continued their recent momentum with a 28% gain in the last month...
Articolo di analisi • Feb 20

Improved Revenues Required Before Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Find Their Feet

With a price-to-sales (or "P/S") ratio of 6.3x Nurix Therapeutics, Inc. ( NASDAQ:NRIX ) may be sending very bullish...
Seeking Alpha • Jan 16

Nurix Therapeutics: Recovering Thanks To ASH, But I Think It's Priced Just Right For Now

Summary Nurix Therapeutics remains a highly interesting science project, but the rubber has yet to hit the road on their clinical projects. The company's BTK degraders are showing early signs of life, but the competition in the market and expenses are concerns. Nurix has enough assets to fund operations for another 6 to 7 quarters, but a cash infusion may be needed later this year. Read the full article on Seeking Alpha
Articolo di analisi • Dec 29

Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Articolo di analisi • Oct 14

Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 29% Dip In Price Shows Sentiment Is Matching Revenues

To the annoyance of some shareholders, Nurix Therapeutics, Inc. ( NASDAQ:NRIX ) shares are down a considerable 29% in...
Articolo di analisi • Oct 13

Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher

Shareholders in Nurix Therapeutics, Inc. ( NASDAQ:NRIX ) may be thrilled to learn that the analysts have just delivered...
Articolo di analisi • Sep 30

Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Articolo di analisi • Apr 18

Party Time: Brokers Just Made Major Increases To Their Nurix Therapeutics, Inc. (NASDAQ:NRIX) Earnings Forecasts

Nurix Therapeutics, Inc. ( NASDAQ:NRIX ) shareholders will have a reason to smile today, with the analysts making...
Articolo di analisi • Apr 15

We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Articolo di analisi • Nov 28

We're Keeping An Eye On Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Stabilità e crescita dei pagamenti

Recupero dei dati sui dividendi

Dividendo stabile: Dati insufficienti per determinare se i dividendi per azione di NRIX siano rimasti stabili in passato.

Dividendo in crescita: Dati insufficienti per determinare se i pagamenti dei dividendi di NRIX siano aumentati.

Rendimento dei dividendi rispetto al mercato

Nurix Therapeutics Rendimento dei dividendi rispetto al mercato
Come si colloca il rendimento da dividendo di NRIX rispetto al mercato?
SegmentoRendimento dei dividendi
Azienda (NRIX)n/a
Fondo del 25% del mercato (US)1.4%
Top 25% del mercato (US)4.3%
Media del settore (Biotechs)2.4%
Analista previsionale (NRIX) (fino a 3 anni)0%

Dividendo notevole: Impossibile valutare il rendimento dei dividendi di NRIX rispetto al 25% inferiore dei pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Dividendo elevato: Impossibile valutare il rendimento dei dividendi di NRIX rispetto al 25% dei maggiori pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Distribuzione degli utili agli azionisti

Copertura degli utili: Dati insufficienti per calcolare il payout ratio di NRIX per determinare se i suoi pagamenti di dividendi sono coperti dagli utili.

Pagamenti in contanti agli azionisti

Copertura del flusso di cassa: Impossibile calcolare la sostenibilità dei dividendi poiché NRIX non ha segnalato alcun pagamento.

Scoprire le società che pagano dividendi forti

7D

1Y

7D

1Y

7D

1Y

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/05/21 02:29
Prezzo dell'azione a fine giornata2026/05/21 00:00
Utili2026/02/28
Utili annuali2025/11/30

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Nurix Therapeutics, Inc. è coperta da 25 analisti. 17 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Brian SkorneyBaird
Joel BeattyBaird
Zhiqiang ShuBerenberg